PARAMOMYCIN
Indication
Pharmacokinetics.
Pharmacodynamics
MOA
Inhibits protein synthesis by binding to 16S ribosomal
Acute and chronic intestinal amebiasis
Hepatic
Dientamoeba fragilis infection
Broad spectrum aminoglycoside antibiotic produced by Streptomyces rimosus var. paromomycinus.
Distribution
Metabolism
Absorption
Excretion
Poorly absorbed after oral administration
Not available
Not available.
100% of the drug recoverable in the stool
Adverse effects
Diarrhea, Pruritus, Hypocholestreroalemia, Headavhe, vertigo and haematuria.
Potentially fatal : Pseudomembranous colitis, nephrotoxicity, neuromuscular blockade.
Ototoxicity, anorexia, nausea, vomiting, epigastric pain, increased GI motility,abdominal cramp.
Bacterial proteins are synthesized by ribosomal RNA complexes which are composed of 2 subunits, a large subunit (50s) and small (30s) subunit, which forms a 70s ribosomal subunit. tRNA binds to the top of this ribosomal structure. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death